Cover Image
市場調查報告書

過敏性鼻炎治療藥的全球市場 (2018年∼2028年):口服抗組織胺藥物,皮質類固醇滴鼻劑,抗組織胺滴鼻劑,免疫療法·疫苗

Global Allergic Rhinitis Drugs Market 2018-2028: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines

出版商 Visiongain Ltd 商品編碼 310754
出版日期 內容資訊 英文 256 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
過敏性鼻炎治療藥的全球市場 (2018年∼2028年):口服抗組織胺藥物,皮質類固醇滴鼻劑,抗組織胺滴鼻劑,免疫療法·疫苗 Global Allergic Rhinitis Drugs Market 2018-2028: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines
出版日期: 2018年08月24日 內容資訊: 英文 256 Pages
簡介

全球過敏性鼻炎治療藥市場在2017年為122億美元,預計到2022年前將達143億美元,以3.3%的年複合成長率 (CAGR) 增長。

本報告提供全球過敏性鼻炎治療藥市場相關調查分析,提供市場概要,各市場區隔的市場分析與預測,各地區·各國市場分析與預測,主要企業等相關的系統性資訊。

第1章 分析概要

第2章 過敏性鼻炎治療藥的概要

  • 製藥產業:概要
  • 過敏概要
  • 過敏性鼻炎
  • 過敏性鼻炎的治療方法
  • 臨床實驗的階段
  • 分析範圍

第3章 全球過敏性鼻炎治療藥的市場

  • 過敏性鼻炎治療藥:市場概要
  • 市場分類
  • 全球市場
  • 市場未來預測 (今後11年份)
  • 各部門的市場佔有率 (今後11年份)

第4章 口服抗組織胺藥物市場:分析與預測

  • 口服抗組織胺藥物:市場概要
    • 口服抗組織胺藥物市場主要產品
  • 口服抗組織胺藥物:市場趨勢和動靜
    • 專利到期和仿製藥的威脅
    • 由處方藥轉變成藥
    • 皮質類固醇滴鼻劑的聯合治療可能性
  • 市場未來預測 (今後11年份)
    • 主要產品的市場佔有率的變動預測
  • 有代表性的口服抗組織胺藥物 (全9產品)

第5章 皮質類固醇滴鼻劑市場:分析與預測

  • 皮質類固醇滴鼻劑市場主要產品
  • 市場未來預測 (今後11年份)
    • 主要產品的市場佔有率的變動預測
  • 有代表性的皮質類固醇滴鼻劑產品 (全9產品)

第6章 免疫療法·疫苗市場:分析與預測

  • 免疫療法·疫苗:市場概要
    • 免疫療法:迅速市場成長的徵兆
  • 免疫療法的主要產品
  • 過敏性鼻炎:市場趨勢和動靜
    • 皮下/舌下免疫療法
    • 美國市場的成長
    • 免疫療法產品的標準化
    • 預防的治療方法的免疫療法
  • 市場未來預測 (今後11年份)
    • 主要產品的市場佔有率的變動預測
  • 免疫療法的種類:投藥各途徑
  • 過敏性鼻炎免疫療法的代表性產品 (全6產品)

第7章 抗組織胺滴鼻劑市場:分析與預測

  • 抗組織胺滴鼻劑:主要產品
  • 抗組織胺滴鼻劑:市場趨勢和動靜
    • Azelastine vs Olopatadine
    • 並用型滴鼻劑
  • 市場未來預測 (今後11年份)
    • 主要產品的市場佔有率的變動預測
  • 抗組織胺滴鼻劑的代表性產品 (全5種產品)

第8章 主要國家的過敏性鼻炎治療藥市場

  • 各地區的市場規模·佔有率
  • 主要國家市場趨勢預測 (今後12年份)
    • 各地區市場佔有率的變動預測
  • 主要國家市場:分析與預測 (今後12年份)
    • 美國, (EU5歐洲主要5個國家),中國,日本,俄羅斯,印度,巴西等

第9章 過敏性鼻炎治療藥市場主要企業

  • 過敏性鼻炎治療藥:市場結構的變化
    • 主要企業一覽
  • ALK-Abello
    • 產品系列
    • 近幾年趨勢
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Merck & Co.
  • Sanofi
  • Stallergenes Greer
  • UCB
  • 其他的企業

第10章 過敏性鼻炎治療藥:研究開發 (R&D) 開發平台(管線)

  • 過敏性鼻炎治療藥的開發中產品:趨勢和動靜
  • 口服抗組織胺藥物的研究開發平台 (全2產品)
  • 皮質類固醇滴鼻劑的研究開發平台 (全2產品)
  • 免疫療法的研究開發平台 (全7產品)
  • 其他的治療藥物的研究開發平台 (全5種產品)

第11章 過敏性鼻炎治療藥市場定性分析

  • 過敏性鼻炎治療藥對市場的影響要素
  • SWOT分析
  • 波特的五力分析

第12章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0328

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.3% in the first half of the forecast period. The market is estimated at $12.2bn in 2017 and $14.3bn in 2022.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 256-page report you will receive 97 tables and 100 figures - all unavailable elsewhere.

The 256-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Allergic Rhinitis Drugs Market forecasts from 2018-2028
  • Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2028 for the following submarkets :
  • Intranasal Antihistamines
  • Intranasal Corticosteroids
  • Oral Antihistamines
  • Immunotherapy and Vaccines

image1

  • How will leading allergic rhinitis drugs perform to 2028 at world level? Our study forecasts individual revenues of these 27 products:
    • Patanase
    • Astepro
    • Astelin
    • Dymista
    • Nasonex
    • Avamys
    • Veramyst
    • Flixonase
    • Rhinocort
    • Omnaris
    • Nasacort
    • Beconase
    • Qnasl
    • Zetonna
    • Allegra
    • Zyrtec
    • Claritin
    • Xyzal
    • Allelock
    • Clarinex
    • Ebastel
    • Talion
    • Staloral
    • Alutard SQ
    • Grazax
    • Ragwitek
    • Generic Azelastine
  • This report provides individual revenue forecasts to 2028 for these regional and national markets:
    • US
    • EU5 - Germany, UK, France, Italy and Spain
    • China
    • Japan
    • India
    • Russia
    • Brazil
    • Rest of the World

Each national market is further segmented by submarket.

  • Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market:
    • GlaxoSmithKline (GSK)
    • Merck & Co
    • Sanofi
    • Johnson & Johnson
    • ALK-Abello
    • UCB
    • Kyowo Hako Kirin
    • Stallergenes Greer
  • This report discusses the trends and development in the allergic rhinitis pipeline
  • Our study discusses strengths, weaknesses, opportunities and threats as well as porter's five forces analysis of the global allergic rhinitis drugs market

Visiongain's study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Allergic Rhinitis Drugs: Market Overview
  • 1.2 Global Allergic Rhinitis Drugs Market Segmentation
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Key Questions Answered by This Analytical Report
  • 1.8 Who is This Report For?
  • 1.9 Methodology
  • 1.10 Frequently Asked Questions (FAQ)
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2. An Introduction to Allergic Rhinitis Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1 Allergic Rhinitis Treatments - An Industry Overview
  • 2.2 A Brief Overview of Allergy
  • 2.3 Allergic Rhinitis
    • 2.3.1 The Global Prevalence of Allergic Rhinitis
    • 2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
    • 2.3.3 Symptoms of Allergic Rhinitis
    • 2.3.4 Classification of Allergic Rhinitis
    • 2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
    • 2.3.6 Perennial Allergic Rhinitis
    • 2.3.7 Diagnosis of Allergic Rhinitis
  • 2.4 Treatment of Allergic Rhinitis
    • 2.4.1 Antihistamines
    • 2.4.2 Corticosteroids
    • 2.4.3 Leukotriene Receptor Antagonists
    • 2.4.4 Cromolyn (cromoglicic acid)
    • 2.4.5 Decongestants
    • 2.4.6 Saline Nasal Sprays
    • 2.4.7 Immunotherapy and Vaccines
  • 2.5 Phases of Clinical Trials
  • 2.6 Scope of this Report

3. The Global Allergic Rhinitis Drugs Market, 2018-2028

  • 3.1 The Global Allergic Rhinitis Drugs Market: Market Overview
  • 3.2 Categorisation of The Global Allergic Rhinitis Drugs Market
  • 3.3 The Global Allergic Rhinitis Drugs Market in 2017
  • 3.4 The Global Allergic Rhinitis Drugs Market: Market Forecast 2018-2028
  • 3.5 Allergic Rhinitis Drugs: Changing Market Shares by Sector 2018-2028

4. Oral Antihistamines Market: Market Analysis and Forecast 2018-2028

  • 4.1 Oral Antihistamines: Market Overview
    • 4.1.1 Leading Products in the Oral Antihistamines Market, 2017
  • 4.2 Oral Antihistamines: Market Trends and Developments, 2018
    • 4.2.1 Patent Expiries and the Threat of Generics
    • 4.2.2 The Increasing Switch from Prescription to Over-The-Counter Sales
    • 4.2.3 The Potential for Combination Therapy with Intranasal Corticosteroids
  • 4.3 Oral Antihistamines: Market Forecast 2018-2028
    • 4.3.1 Oral Antihistamines: Changing Market Shares by Leading Drugs 2018-2028
  • 4.4 Leading Oral Antihistamines for the Treatment of Allergic Rhinitis
    • 4.4.1 Allegra/Allegra-D/Allegra OTC (fexofenadine) - Sanofi
    • 4.4.2 Claritin/Claritin OTC (loratadine) - Bayer/ Merck & Co
    • 4.4.3 Zyrtec/Zyrtec D (cetirizine) - Johnson & Johnson/ UCB/ GSK
    • 4.4.4 Xyzal (levocetirizine) - Sanofi/ UCB/ GSK
    • 4.4.5 Clarinex (desloratadine) - Merck & Co.
    • 4.4.6 Allelock (olopatadine) - Kyowa Hakko Kirin
    • 4.4.7 Ebastel (ebastine) - AstraZeneca/Takeda/Dainippon Sumitomo
    • 4.4.8 Talion (bepotastine) - Mitsubishi Tanabe
    • 4.4.9 Other Oral Antihistamines: Sales Forecast 2018-2028

5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2018-2028

  • 5.1 Leading Products in the Intranasal Corticosteroids Market, 2017
  • 5.2 Intranasal Corticosteroids: Market Forecast 2018-2028
    • 5.2.1 Intranasal Corticosteroids: Changing Market Shares by Leading Drugs 2018-2028
  • 5.3 Leading Intranasal Corticosteroids
    • 5.3.1 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) - GlaxoSmithKline
    • 5.3.2 Nasonex (mometasone) - Merck
    • 5.3.3 Avamys/Veramyst (fluticasone furoate) - GlaxoSmithKline
    • 5.3.4 Rhinocort (budesonide) - AstraZeneca
    • 5.3.5 Nasacort/Nasacort-OTC (triamcinolone) - Sanofi
    • 5.3.6 Omnaris (ciclesonide) - Dainippon Sumitomo/Takeda
    • 5.3.7 Beconase/Beconase AQ (beclometasone) - GlaxoSmithKline/Omega Pharma
    • 5.3.8 Qnasl (beclometasone) - Teva
    • 5.3.9 Zetonna (ciclesonide) - Dainippon Sumitomo

6. Immunotherapy and Vaccines: Market Analysis and Forecast 2018-2028

  • 6.1 Immunotherapy and Vaccines: Market Overview
    • 6.1.1 Immunotherapy: Primed for Rapid Expansion
  • 6.2 Leading Immunotherapy Products in the Allergic Rhinitis Market, 2017
  • 6.3 Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2017
    • 6.3.1 Subcutaneous and Sublingual Immunotherapy
    • 6.3.2 Expansion into the US Market
    • 6.3.3 Standardisation of Immunotherapy Products
    • 6.3.4 Immunotherapy as a Preventative Treatment
  • 6.4 Allergic Rhinitis Immunotherapy: Market Forecast 2018-2028
    • 6.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2018-2028
  • 6.5 Immunotherapy Type - By Route of Administration, 2017
  • 6.6 Leading Immunotherapy Products for Allergic Rhinitis
    • 6.6.1 Staloral (Grass pollen allergen extract) - Stallergenes
    • 6.6.2 Alutard SQ (Grass pollen allergen extract) - ALK-Abelló
    • 6.6.3 Grazax/Grastek (Timothy grass pollen allergen extract) - ALK-Abelló/Merck
    • 6.6.4 Oralair (Grass pollen allergen extract) - Stallergenes/Greer
    • 6.6.5 Ragwitek (Short ragweed pollen allergen extract) - Merck
    • 6.6.6 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2018-2028

7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2018-2028

  • 7.1 Leading Products in the Intranasal Antihistamines Market, 2017
  • 7.2 Intranasal Antihistamines: Market Trends and Developments, 2018
    • 7.2.1 Azelastine versus Olopatadine
    • 7.2.2 Intranasal Combination Products
  • 7.3 Intranasal Antihistamines: Market Forecast 2018-2028
    • 7.3.1 Intranasal Antihistamines: Changing Market Shares by Leading Drugs 2018-2028
  • 7.4 Leading Intranasal Antihistamines
    • 7.4.1 Dymista (azelastine/fluticasone) - Meda Pharmaceuticals
    • 7.4.2 Generic Intranasal Azelastine
    • 7.4.3 Astepro (azelastine) - Meda Pharmaceuticals
    • 7.4.4 Patanase (olopatadine) - Novartis
    • 7.4.5 Astelin (azelastine) - Meda Pharmaceuticals

8. Leading National Markets for Allergic Rhinitis Drugs, 2017-2028

  • 8.1 The Allergic Rhinitis Drugs Market by Region
    • 8.1.1 The Global Distribution of Allergic Rhinitis Drugs in 2017
  • 8.2 Leading National Markets: Forecast 2017-2028
    • 8.2.1 Changing Market Shares by Region, 2017-2028
  • 8.3 Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2017-2028
    • 8.3.1 United States: The Largest Allergic Rhinitis Drugs Market
    • 8.3.2 EU5
  • 8.4 China
  • 8.5 Japan
  • 8.6 Russia
  • 8.7 India
  • 8.8 Brazil
  • 8.9 Rest of the World

9. Leading Companies in the Allergic Rhinitis Drugs Market, 2017-2028

  • 9.1 Allergic Rhinitis Drugs - An Evolving Market Space
    • 9.1.1 Leading Companies in the Allergic Rhinitis Drugs Market, 2018
  • 9.2 ALK-Abelló
    • 9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.2.2 ALK-Abelló: Recent Developments
  • 9.3 GlaxoSmithKline (GSK)
    • 9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.3.2 GlaxoSmithKline: Sales Forecast 2017-2028
  • 9.4 Johnson & Johnson
    • 9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.4.2 Johnson & Johnson: Recent Developments
  • 9.5 Kyowa Hakko Kirin
    • 9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.5.2 Kyowa Hakko Kirin: Sales Forecast 2017-2028
  • 9.6 Merck & Co.
    • 9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.6.2 Merck: Recent Developments
  • 9.7 Sanofi
    • 9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.7.2 Sanofi: Sales Forecast 2017-2028
    • 9.7.3 Sanofi: Recent Developments
  • 9.8 Stallergenes Greer
    • 9.8.1 Stallergenes: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.8.2 Stallergenes Greer: Sales Forecast 2017-2028
    • 9.8.3 Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2018
  • 9.9 UCB
    • 9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2018
    • 9.9.2 UCB: Sales Forecast 2017-2028
  • 9.10 Other Leading Companies within the Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2017-2028

  • 10.1 Trends and Developments in the Allergic Rhinitis Pipeline
  • 10.2 The R&D Pipeline for Oral Antihistamines, 2018
    • 10.2.1 Talion (bepotastine) - Mitsubishi Tanabe
    • 10.2.2 ZPL-3893787 (histamine H4R antagonist) - Ziarco Pharma
  • 10.3 The R&D Pipeline for Intranasal Corticosteroids, 2018
    • 10.3.1 APC-3000 (HFA inhaled corticosteroid) - Adamis Pharmaceuticals
    • 10.3.2 TBS-6 - Trimel Pharmaceuticals
  • 10.4 The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2018
    • 10.4.1 Actair (house dust mite SLIT; STG320) - Stallergenes/Shionogi & Co
    • 10.4.2 AllerT (subcutaneous birch pollen immunotherapy) - Anergis
    • 10.4.3 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma
    • 10.4.4 House Dust Mite SLIT-Tablet (MK-8237) - ALK-Abelló/Merck/Torii
    • 10.4.5 Pollinex Quattro (subcutaneous immunotherapies) - Allergy Therapeutics
    • 10.4.6 gp-ASIT+ (grass pollen allergen fragments) - Biotech Tools
    • 10.4.7 Betula verrucosa (Bet v) 1 allergen - Stallergenes Greer
  • 10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs
    • 10.5.1 S-555739 (prostaglandin D2 receptor antagonist) - Shionogi
    • 10.5.2 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) - Dainippon Sumitomo/ AstraZeneca
    • 10.5.3 GSK2245035 (toll-like receptor 7 agonist) - GSK
    • 10.5.4 HP-3060 (transdermal long-acting tape) - Hisamitsu
    • 10.5.5 MRX-4 (anti-inflammatory agent) - Celsus Therapeutics

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2017-2028

  • 11.1 Market Factors Influencing Allergic Rhinitis Drugs
  • 11.2 SWOT Analysis of The Global Allergic Rhinitis Drugs Market, 2017-2028
    • 11.2.1 Strengths
    • 11.2.2 Weaknesses
    • 11.2.3 Opportunities
    • 11.2.4 Threats
  • 11.3 Porter's Five Forces Analysis of the Global Allergic Rhinitis Drugs Market, 2017-2028
    • 11.3.1 Power of Buyers
    • 11.3.2 Power of Suppliers
    • 11.3.3 Threat of Substitutes
    • 11.3.4 Threat 0f New Entrants
    • 11.3.5 Rivalry Among Competitors

12. Conclusion

  • 12.1 Overview of Current Market Conditions and Market Forecast, 2017-2028
  • 12.2 Leading Sectors in the Allergic Rhinitis Drugs Market in 2017
  • 12.3 Leading Regions in the Allergic Rhinitis Drugs Market in 2017
  • 12.4 Leading Companies in the Allergic Rhinitis Drugs Market, 2017
  • 12.5 What Does the Future Hold for Allergic Rhinitis Drugs?

Associated Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 (Sample) Allergic Rhinitis Market Forecast by National Market: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2018
  • Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2018
  • Table 2.3 Clinical Trial Phases
  • Table 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2017
  • Table 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028
  • Table 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2017, 2022, 2028
  • Table 4.1 Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2017
  • Table 4.2 Oral Antihistamines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.3 The Global Oral Antihistamines Market: Market Share (%), 2017, 2022, 2028
  • Table 4.4 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.5 Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.6 Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.7 Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.8 Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.9 Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.10 Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.11 Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.12 Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.1 Leading Drugs in The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2017
  • Table 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 5.3 The Global Intranasal Corticosteroids Market: Market Share (%), 2017, 2022, 2028
  • Table 5.4 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2017-2028
  • Table 5.5 Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.6 Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.7 Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.8 Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.9 Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.10 Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.11 Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.12 Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2017
  • Table 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2017, 2022, 2028
  • Table 6.4 Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2017
  • Table 6.5 Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.6 Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.7 Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.8 Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.9 Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.10 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 7.1 Top Drugs in The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2017
  • Table 7.2 Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2017-2028
  • Table 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2017, 2022 and 2028
  • Table 7.4 Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 7.5 Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 7.6 Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 7.7 Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 7.8 Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2017
  • Table 8.2 Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2017, 2022, and 2028
  • Table 8.4 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.5 US Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.6 The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2017
  • Table 8.7 The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.8 The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2017, 2022, 2028
  • Table 8.9 Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.10 Germany Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.11 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.12 UK Allergic Rhinitis Drugs Market Forecast By Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.13 France Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2017-2028
  • Table 8.14 France Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.15 Italy Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2017-2028
  • Table 8.16 Italy Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.17 Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2017-2028
  • Table 8.18 Spain Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.19 China Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.20 China Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.21 Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2017-2028
  • Table 8.22 Japan Allergic Rhinitis Drugs Market Forecast By Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.23 Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.24 Russia Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.25 India Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.26 India Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.27 Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.28 Brazil Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.29 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2017-2028
  • Table 8.30 Rest of the world Allergic Rhinitis Drugs Market Forecast by Segment: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 9.1 Leading Companies in the Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2017
  • Table 9.2 ALK- Abelló: Company Overview, 2018
  • Table 9.3 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 9.4 GlaxoSmithKline: Company Overview, 2018
  • Table 9.5 GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 9.6 Johnson & Johnson: Company Overview, 2018
  • Table 9.7 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 9.8 Kyowa Hakko Kirin: Company Overview, 2018
  • Table 9.9 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 9.10 Merck & Co.: Company Overview, 2018
  • Table 9.11 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028
  • Table 9.12 Sanofi: Company Overview, 2018
  • Table 9.13 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028
  • Table 9.14 Stallergenes Greer: Company Overview, 2018
  • Table 9.15 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028
  • Table 9.16 UCB: Company Overview, 2018
  • Table 9.17 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028
  • Table 11.1 SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2017-2028

List of Figures

  • Figure 1.1 Global Allergic Rhinitis Drugs Market: Market Sectors, 2017
  • Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2017
  • Figure 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2017
  • Figure 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2017-2028
  • Figure 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2017
  • Figure 3.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2022
  • Figure 3.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2028
  • Figure 4.1 Leading Oral Antihistamines: Revenue ($m), 2017
  • Figure 4.2 Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.3 The Global Oral Antihistamines Market: Market Share (%), 2017
  • Figure 4.4 The Global Oral Antihistamines Market: Market Share (%), 2022
  • Figure 4.5 The Global Oral Antihistamines Market: Market Share (%), 2028
  • Figure 4.6 Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2017
  • Figure 4.7 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.8 Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.9 Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.10 Xyzal Forecast: Revenue($m) and AGR (%), 2017-2028
  • Figure 4.11 Clarinex Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.12 Allelock Forecast: Revenue($m) and AGR (%), 2017-2028
  • Figure 4.13 Ebastel Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.14 Talion Forecast: Revenue($m) and AGR (%), 2017-2028
  • Figure 4.15 Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2017
  • Figure 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.3 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2017
  • Figure 5.4 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2022
  • Figure 5.5 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2028
  • Figure 5.6 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.7 Nasonex Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.8 Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.9 Rhinocort Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.10 Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.11 Omnaris Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.12 Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.13 Qnasl Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.14 Zetonna Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2017
  • Figure 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2017
  • Figure 6.4 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2022
  • Figure 6.5 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2028
  • Figure 6.6 Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2017
  • Figure 6.7 Staloral Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.8 Alutard SQ Forecast: Revenue($m) and AGR (%), 2017-2028
  • Figure 6.9 Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2017-2028
  • Figure 6.10 Oralair Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.11 Ragwitek Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.12 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 7.1 Top Drugs in The Intranasal Antihistamines Market: Revenue ($m), 2017
  • Figure 7.2 Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2017
  • Figure 7.4 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2022
  • Figure 7.5 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2028
  • Figure 7.6 Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 7.7 Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2017-2028
  • Figure 7.8 Astepro Forecast: Revenue ($m), and AGR (%), 2017-2028
  • Figure 7.9 Patanase Forecast: Revenue($m) and AGR (%), 2017-2028
  • Figure 7.10 Astelin Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m), 2017
  • Figure 8.2 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2017
  • Figure 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2022
  • Figure 8.4 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2028
  • Figure 8.5 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.6 US Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.7 The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2017
  • Figure 8.8 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2017
  • Figure 8.9 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2022
  • Figure 8.10 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2028
  • Figure 8.11 Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.12 Germany Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.13 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.14 UK Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.15 France Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.16 France Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.17 Italy Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.18 Italy Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.19 Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.20 Spain Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.21 China Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.22 China Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.23 Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.24 Japan Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.25 Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.26 Russia Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.27 India Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.28 India Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.29 Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.30 Brazil Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 8.31 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 8.32 Rest of the world Allergic Rhinitis Drugs Market by Segment: Revenue ($m), 2017
  • Figure 9.1 Leading Companies in the Allergic Rhinitis Drug Market: Revenues ($m), 2017
  • Figure 9.2 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 9.3 GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 9.4 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 9.5 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 9.6 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 9.7 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2017-2028
  • Figure 9.8 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2017-2028
  • Figure 9.9 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2017-2028
  • Figure 11.1 Porter's Five Forces Analysis of the Allergic Rhinitis Drugs Market, 2018

COMPANIES LISTED

  • ActoGeniX
  • Adamis Pharmaceuticals
  • ALK- Abelló
  • Allergy Medical UK
  • Allergy Therapeutics
  • Almirall
  • Altana Pharma (Nycomed)
  • Anergis
  • Apotex
  • AstraZeneca
  • Atopix Therapeutics
  • Barr Laboratories
  • Bausch & Lomb
  • Belcher Pharmaceuticals
  • Biotech Tools
  • Catalent Pharma Solutions
  • Celsus Therapeutics
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy's Laboratories
  • Eddingpharm
  • Eleventa
  • Genzyme (Sanofi)
  • GlaxoSmithKline
  • Greer Laboratories
  • Hisamitsu Pharmaceutical Co
  • Hoechst AG
  • Human Genome Sciences
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Keldman Healthcare
  • Kyowa Hakko Kirin
  • Leti Pharma (Laboratorios Leti)
  • Lupin Pharmaceuticals
  • Meda Pharma
  • Medpointe Inc (Meda Pharma)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nippon Paper Group
  • Novartis
  • Omega Pharma
  • Perrigo
  • Pfizer
  • ProStrakan (Kyowa Hakko Kirin)
  • Reckitt Benckiser
  • Roxane Laboratories (Boehringer Ingelheim)
  • Sanofi
  • Schering-Plough (Merck)
  • Shionogi & Co Ltd
  • Stallergenes
  • Sun Pharmaceuticals
  • Sunovion Pharmaceuticals (Dainippon Sumitomo)
  • Takeda
  • Teva Pharmaceuticals
  • Trimel Pharmaceuticals
  • Ube Industries
  • UCB
  • ViiV Healthcare
  • Wockhardt
  • Ziarco Pharma

Organizations Mentioned in the Report

  • Allergy & Asthma Network
  • AllergyUK
  • American Academy of Allergy, Asthma and Immunology (AAAAI)
  • British Society for Allergy & Clinical Immunology (BSACI) [UK]
  • Farmácia Popular [Brazil]
  • Imperial College London
  • International Nurses Group In Immunodeficiencies
  • Japanese Ministry of Health, Labour and Welfare
  • Les Entreprises Du Médicament (Leem) [France]
  • National Development and Reform Commission (NDRC) [China]
  • National Pharmaceutical Pricing Authority (NPPA) [India]
  • PollenUK
  • The Pharmaceutical Research and Manufacturers of America (PhRMA)
  • The UK Health and Social Care Information Centre
  • Université Libre de Bruxelles [Belgium]
  • University of Leuven [Belgium]
  • US Attorney's Office for the Eastern District of Pennsylvania
  • US Food and Drug Administration (FDA)
  • World Allergy Organisation
  • World Health Organisation (WHO)

List of Tables

  • Table 1.1: (Sample) Allergic Rhinitis Market Forecast by National Market: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 2.1: Leading Antihistamines for Allergic Rhinitis, 2017
  • Table 2.2: Leading Corticosteroids for Allergic Rhinitis, 2017
  • Table 2.3: Clinical Trial Phases
  • Table 3.1: The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2016
  • Table 3.2: The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 3.3: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016, 2021, 2027
  • Table 4.1: Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2016
  • Table 4.2: Oral Antihistamines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3: The Global Oral Antihistamines Market: Market Share (%), 2016, 2021, 2027
  • Table 4.4: Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.5: Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6: Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.7: Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8: Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10: Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.11: Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12: Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1: Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2016
  • Table 5.2: Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3: The Global Intranasal Corticosteroids Market: Market Share (%), 2016, 2021, 2027
  • Table 5.4: Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 5.5: Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.6: Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.7: Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.8: Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.9: Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.10: Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.11: Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.12: Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1: Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2016
  • Table 6.2: Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016, 2021, 2027
  • Table 6.4: Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2016
  • Table 6.5: Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.6: Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.7: Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8: Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.9: Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.10: Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1: Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2016
  • Table 7.2: Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2016-2027
  • Table 7.3: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
  • Table 7.4: Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.5: Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.6: Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.7: Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.8: Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.1: The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2016
  • Table 8.2: Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.3: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016, 2021, and 2027
  • Table 8.4: US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.5: The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2016
  • Table 8.6: The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.7: The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2016, 2021, 2027
  • Table 8.8: Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.9: UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.10: France Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.11: Italy Allergic Rhinitis Drugs Market Forecat: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.12: Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.13: China Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.14: Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
  • Table 8.15: Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.16: India Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.17: Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 8.18: Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.1: Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2016
  • Table 9.2: ALK- Abelló: Company Overview, 2017
  • Table 9.3: ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.4: GlaxoSmithKline: Company Overview, 2017
  • Table 9.5: GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.6: Johnson & Johnson: Company Overview, 2017
  • Table 9.7: Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.8: Kyowa Hakko Kirin: Company Overview, 2017
  • Table 9.9: Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 9.10: Merck & Co.: Company Overview, 2017
  • Table 9.11: Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.12: Sanofi: Company Overview, 2017
  • Table 9.13: Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.14: Stallergenes Greer: Company Overview, 2016
  • Table 9.15: Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.16: UCB: Company Overview, 2017
  • Table 9.17: UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 11.1: SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027

List of Figures

  • Figure 1.1: Global Allergic Rhinitis Drugs Market: Market Sectors, 2017
  • Figure 2.1: Role of Mast Cells and IgE in Allergic Rhinitis, 2017
  • Figure 3.1: The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2016
  • Figure 3.2: The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2016-2027
  • Figure 3.3: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016
  • Figure 3.4: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2021
  • Figure 3.5: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2027
  • Figure 4.1: Leading Oral Antihistamines: Revenue ($m), 2016
  • Figure 4.2: Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.3: The Global Oral Antihistamines Market: Market Share (%), 2016
  • Figure 4.4: The Global Oral Antihistamines Market: Market Share (%), 2021
  • Figure 4.5: The Global Oral Antihistamines Market: Market Share (%), 2027
  • Figure 4.6: Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2016
  • Figure 4.7: Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.8: Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.9: Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.10: Xyzal Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 4.11: Clarinex Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.12: Allelock Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 4.13: Ebastel Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 4.14: Talion Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 4.15: Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.1: Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2016
  • Figure 5.2: Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.3: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2016
  • Figure 5.4: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2021
  • Figure 5.5: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2027
  • Figure 5.6: Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.7: Nasonex Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.8: Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.9: Rhinocort Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.10: Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.11: Omnaris Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.12: Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.13: Qnasl Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.14: Zetonna Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.1: Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2016
  • Figure 6.2: Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.3: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016
  • Figure 6.4: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2021
  • Figure 6.5: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2027
  • Figure 6.6: Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2016
  • Figure 6.7: Staloral Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.8: Alutard SQ Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 6.9: Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 6.10: Oralair Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.11: Ragwitek Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.12: Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.1: Top Drugs in The Intranasal Antihistamines Market: Revenue ($m), 2016
  • Figure 7.2: Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 7.3: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016
  • Figure 7.4: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2021
  • Figure 7.5: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2027
  • Figure 7.6: Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.7: Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2016-2027
  • Figure 7.8: Astepro Forecast: Revenue ($m), and AGR (%), 2016-2027
  • Figure 7.9: Patanase Forecast: Revenue($m) and AGR (%), 2016-2027
  • Figure 7.10: Astelin Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 8.1: The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m), 2016
  • Figure 8.2: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016
  • Figure 8.3: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2021
  • Figure 8.4: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2027
  • Figure 8.5: US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.6: The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2016
  • Figure 8.7: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2016
  • Figure 8.8: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2021
  • Figure 8.9: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2027
  • Figure 8.10: Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.11: UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.12: France Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.13: Italy Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.14: Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.15: China Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.16: Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.17: Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.18: India Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.19: Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.20: Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.1: Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m), 2016
  • Figure 9.2: ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 9.3: GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.4: Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.5: Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.6: Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 9.7: Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.8: Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.9: UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 11.1: Porter's Five Forces Analysis of the Allergic Rhinitis Drugs Market, 2017

Companies Listed

  • ActoGeniX
  • Adamis Pharmaceuticals
  • ALK- Abelló
  • Allergy Medical UK
  • Allergy Therapeutics
  • Almirall
  • Altana Pharma (Nycomed)
  • Anergis
  • Apotex
  • AstraZeneca
  • Atopix Therapeutics
  • Barr Laboratories
  • Bausch & Lomb
  • Belcher Pharmaceuticals
  • Biotech Tools
  • Catalent Pharma Solutions
  • Celsus Therapeutics
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy's Laboratories
  • Eddingpharm
  • Eleventa
  • Genzyme (Sanofi)
  • GlaxoSmithKline
  • Greer Laboratories
  • Hisamitsu Pharmaceutical Co
  • Hoechst AG
  • Human Genome Sciences
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Keldman Healthcare
  • Kyowa Hakko Kirin
  • Leti Pharma (Laboratorios Leti)
  • Lupin Pharmaceuticals
  • Meda Pharma
  • Medpointe Inc (Meda Pharma)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nippon Paper Group
  • Novartis
  • Omega Pharma
  • Perrigo
  • Pfizer
  • ProStrakan (Kyowa Hakko Kirin)
  • Reckitt Benckiser
  • Roxane Laboratories (Boehringer Ingelheim)
  • Sanofi
  • Schering-Plough (Merck)
  • Shionogi & Co Ltd
  • Stallergenes
  • Sun Pharmaceuticals
  • Sunovion Pharmaceuticals (Dainippon Sumitomo)
  • Takeda
  • Teva Pharmaceuticals
  • Trimel Pharmaceuticals
  • Ube Industries
  • UCB
  • ViiV Healthcare
  • Wockhardt
  • Ziarco Pharma

Organizations Mentioned in the Report

  • Allergy & Asthma Network
  • AllergyUK
  • American Academy of Allergy, Asthma and Immunology (AAAAI)
  • British Society for Allergy & Clinical Immunology (BSACI) [UK]
  • Farmácia Popular [Brazil]
  • Imperial College London
  • International Nurses Group In Immunodeficiencies
  • Japanese Ministry of Health, Labour and Welfare
  • Les Entreprises Du Médicament (Leem) [France]
  • National Development and Reform Commission (NDRC) [China]
  • National Pharmaceutical Pricing Authority (NPPA) [India]
  • PollenUK
  • The Pharmaceutical Research and Manufacturers of America (PhRMA)
  • The UK Health and Social Care Information Centre
  • Université Libre de Bruxelles [Belgium]
  • University of Leuven [Belgium]
  • US Attorney's Office for the Eastern District of Pennsylvania
  • US Food and Drug Administration (FDA)
  • World Allergy Organisation
  • World Health Organisation (WHO)
Back to Top